1187368-66-6

Basic information

• Product Name: 2-fluoro-N,N-dimethyl-4-nitro-benzamide
• Synonyms: 2-fluoro-N,N-dimethyl-4-nitro-benzamide
• CAS NO: 1187368-66-6
• Molecular Weight: 212.18
• Mol File: 1187368-66-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-fluoro-N,N-dimethyl-4-nitro-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-fluoro-N,N-dimethyl-4-nitro-benzamide(1187368-66-6)
• EPA Substance Registry System: 2-fluoro-N,N-dimethyl-4-nitro-benzamide(1187368-66-6)

Safety Data

• Hazardous Substances Data: 1187368-66-6(Hazardous Substances Data)

Upstream product

• 506-59-2 N,N-dimethylammonium chloride 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 
• 403-23-6 2-fluoro-4-nitrobenzoyl chloride 
• 74-89-5 methylamine 

Downstream Products

• 1187368-67-7 2-fluoro-N,N-dimethyl-4-amino-benzamide 
• 1374208-31-7 2-fluoro-N,N-dimethyl-4-(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ureido)-benzamide 
• 1374208-30-6 4-(3-(4-bromophenyl)ureido)-2-fluoro-N,N-dimethyl-benzamide 

Relevant articles and documents

IMIDAZOLIDINEDIONE COMPOUNDS AND THEIR USES

Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds posses androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.